|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0302350,
umls-concept:C0473169,
umls-concept:C0522523,
umls-concept:C0580822,
umls-concept:C1292724,
umls-concept:C1522318,
umls-concept:C1547300,
umls-concept:C1548760,
umls-concept:C1550594,
umls-concept:C1948041
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-12-24
|
|
pubmed:abstractText |
There is great variability among individual patients in platelet inhibition after aspirin intake. Aspirin resistance has been associated with a higher incidence of ischemic events after percutaneous coronary intervention (PCI). The optimal antiplatelet therapy in aspirin-resistant patients undergoing PCI is unknown. The objective of this study was to evaluate whether aggressive antiplatelet therapy would reduce ischemic events in aspirin-resistant patients after PCI.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1557-2501
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
9-13
|
|
pubmed:meshHeading |
pubmed-meshheading:21183763-Adult,
pubmed-meshheading:21183763-Angioplasty, Balloon, Coronary,
pubmed-meshheading:21183763-Antithrombins,
pubmed-meshheading:21183763-Aspirin,
pubmed-meshheading:21183763-Blood Platelets,
pubmed-meshheading:21183763-Drug Resistance,
pubmed-meshheading:21183763-Drug Therapy, Combination,
pubmed-meshheading:21183763-Female,
pubmed-meshheading:21183763-Hirudins,
pubmed-meshheading:21183763-Humans,
pubmed-meshheading:21183763-Male,
pubmed-meshheading:21183763-Middle Aged,
pubmed-meshheading:21183763-Peptide Fragments,
pubmed-meshheading:21183763-Pilot Projects,
pubmed-meshheading:21183763-Platelet Aggregation,
pubmed-meshheading:21183763-Platelet Aggregation Inhibitors,
pubmed-meshheading:21183763-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:21183763-Recombinant Proteins,
pubmed-meshheading:21183763-Ticlopidine
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention.
|
|
pubmed:affiliation |
Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
